Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061004 · ClinicalTrials.gov registry record · NA
Cephea Early Feasibility Study
A NA study of Mitral Regurgitation, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT05061004 is a NA study of Mitral Regurgitation that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 50 participants, below the 1,022-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05061004, a NA study of Mitral Regurgitation, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Conditions Studied
Interventions
- DEVICE Cephea Mitral Valve System
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California - Davis Medical Center - Sacramento
- Los Robles Regional Medical Center - Thousand Oaks
Georgia
- Emory University Hospital - Atlanta
- Piedmont Heart Institute - Atlanta
New York
- New York-Presbyterian/Columbia University Medical Center - New York
- Montefiore Medical Center - Moses Campus - The Bronx
Tennessee
- Ascension Saint Thomas - Nashville
- Vanderbilt Heart & Vascular Institute - Nashville
Arizona
- Banner-University Medical Center Phoenix - Phoenix
Illinois
- Northwestern Memorial Hospital - Chicago
Kansas
- Via Christi Regional Medical Center - St. Francis Campus - Wichita
Michigan
- University of Michigan - Davis Medical Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2031-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05061004
The ClinicalTrials.gov registry entry for NCT05061004 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,022-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (95% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Cephea Mitral Valve System is the first listed.
NCT05061004 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT05061004 about?
NCT05061004 is a clinical study titled "Cephea Early Feasibility Study". The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is ...
What is the current status of trial NCT05061004?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-04-28. Estimated completion is 2031-03-01.
What conditions does trial NCT05061004 study?
This clinical trial studies the following conditions: Mitral Regurgitation.
What interventions are being tested in trial NCT05061004?
The interventions under investigation include: Cephea Mitral Valve System (DEVICE).
Who is sponsoring clinical trial NCT05061004?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05061004 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
RECRUITING · NA
-
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
RECRUITING · NA
-
EFS of the CardioMech MVRS
RECRUITING · NA
-
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
-
The CardioClip Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.